psoralen
Psoralen is the parent compound in a family of naturally occurring organic compounds known as the linear furanocoumarins. It is structurally related to coumarin by the addition of a fused furan ring, and may be considered as a derivative of umbelliferone. Psoralen occurs naturally in the seeds of Psoralea corylifolia, as well as in the common fig, celery, parsley, West Indian satinwood, and in all citrus fruits. It is widely used in PUVA treatment for psoriasis, eczema, vitiligo, and cutaneous T-cell lymphoma; these applications are typically through the use of medications such as Methoxsalen. Many furanocoumarins are extremely toxic to fish, and some are deposited in streams in Indonesia to catch fish. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 1999 (NCT00005092)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DNABINDING AGENT
DNA binding agent
Chemistry & pharmacology
SMILES
O=c1ccc2cc3ccoc3cc2o1- Mol. weight
- 186.17 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPsoralen ↗
- ChEMBLCHEMBL164660 ↗
Also known as
- psoralen
- psoralen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00724061 | N/A | Sep 1, 2008 | National Cancer Institute (NCI), Northwestern University |
| NCT00005092 | Phase 1 | Mar 1, 1999 | National Cancer Institute (NCI), University of Texas at Houston |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 1999 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 1999 |